Literature DB >> 3436314

Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium.

S E Hoffner1, S B Svenson, G Källenius.   

Abstract

A technique to determine the effects of combining antimycobacterial drugs in liquid medium employing the radiometric growth readings in the Bactec system was tested using 20 Mycobacterium avium complex strains. Ten of the strains had been isolated from children with lymphadenopathy and ten from adults with pulmonary disease. All isolates were resistant to streptomycin, rifampicin, isoniazid and ethambutol when tested with a conventional resistant ratio technique on Löwenstein-Jensen medium. Synergistic interactions were shown for the two-drug combinations streptomycin + ethambutol and ethambutol + rifampicin against all 20 strains. Good efficacy was also found for all three-drug combinations containing ethambutol. Thus, although most isolates of the Mycobacterium avium complex are resistant to first-line antituberculous drugs when tested individually, they are susceptible in vitro to certain combinations of these drugs. This rapid radiometric assay is an efficient means for detecting such synergy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3436314     DOI: 10.1007/BF02014241

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  24 in total

1.  Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media.

Authors:  G Middlebrook; Z Reggiardo; W D Tigertt
Journal:  Am Rev Respir Dis       Date:  1977-06

2.  Clinical significance of nontuberculous mycobacteria. A bacteriological survey of Swedish strains isolated between 1973 and 1981.

Authors:  K Wickman
Journal:  Scand J Infect Dis       Date:  1986

3.  Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics.

Authors:  T E Kiehn; F F Edwards; P Brannon; A Y Tsang; M Maio; J W Gold; E Whimbey; B Wong; J K McClatchy; D Armstrong
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

4.  Experimental chemotherapy in chronic Mycobacterium avium-intracellulare infection of mice.

Authors:  F Kuze
Journal:  Am Rev Respir Dis       Date:  1984-03

5.  Treatment of disease due to Mycobacterium intracellulare.

Authors:  P T Davidson; V Khanijo; M Goble; T S Moulding
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

6.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.

Authors:  G CANETTI; S FROMAN; J GROSSET; P HAUDUROY; M LANGEROVA; H T MAHLER; G MEISSNER; D A MITCHISON; L SULA
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

7.  Selecting drug combinations for treatment of drug-resistant mycobacterial diseases.

Authors:  D R Nash; V A Steingrube
Journal:  J Clin Pharmacol       Date:  1982-07       Impact factor: 3.126

8.  Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex.

Authors:  A M Hunter; I A Campbell; P A Jenkins; A P Smith
Journal:  Thorax       Date:  1981-05       Impact factor: 9.139

9.  Improved detection times for Mycobacterium avium complex and Mycobacterium tuberculosis with the BACTEC radiometric system.

Authors:  J M Kirihara; S L Hillier; M B Coyle
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

10.  Use of the BACTEC system for drug susceptibility testing of Mycobacterium tuberculosis, M. kansasii, and M. avium complex.

Authors:  J E Steadham; S K Stall; J L Simmank
Journal:  Diagn Microbiol Infect Dis       Date:  1985-01       Impact factor: 2.803

View more
  29 in total

1.  Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.

Authors:  S Majumdar; D Flasher; D S Friend; P Nassos; D Yajko; W K Hadley; N Düzgüneş
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 2.  Treatment of pulmonary disease caused by opportunist mycobacteria.

Authors:  J Banks
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

3.  Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.

Authors:  U Hjelm; J Kaustová; M Kubín; S E Hoffner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

4.  Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 5.  Mycobacterium avium subsp. paratuberculosis in Veterinary Medicine.

Authors:  N B Harris; R G Barletta
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

6.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

7.  Increased growth of Mycobacterium malmoense in vitro in the presence of isoniazid.

Authors:  S E Hoffner; U Hjelm
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-09       Impact factor: 3.267

Review 8.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

9.  Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

10.  Effects of antimicrobial agents on survival of Mycobacterium avium complex inside alveolar macrophages obtained from patients with human immunodeficiency virus infection.

Authors:  D M Yajko; P S Nassos; C A Sanders; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.